BioTech Scout

Discover the most promising early-stage companies in life sciences, scouted by BioPharmaTrend. Follow company news and important business events.

back to Directory

Intellegens

Intellegens logo

Founded
2017
Publications
6

Technologies

AI Companies (Drug Discovery)

Intellegens is a spin-out from the University of Cambridge that has developed a unique Artificial Intelligence (AI) method for training neural networks from incomplete data sets. The technique, developed in the Department of Physics, is being applied to drug discovery and material design problems.

We have developed a unique capability to train and predict models from incomplete data. The technology can be used to link large, easy to acquire, databases with small, hard to acquire datasets. Generated models can be used to design, predict and identify errors.

Given a fragmented dataset the algorithm can learn the underlying correlations to estimate the missing knowledge of how candidate drugs act on proteins and therefore help clients to design new drug cocktails to activate the right proteins to cure disease